Blood‐based biomarkers for Alzheimer's disease

Blood‐based biomarkers for identifying Alzheimer's disease (AD) pathology have been of considerable interest over the past decade and can offer a significant advantage over the currently available and validated cerebrospinal fluid and positron emission tomography biomarkers in terms of cost, in...

Full description

Saved in:
Bibliographic Details
Published inProgress in neurology and psychiatry (Guildford) Vol. 26; no. 4; pp. 10 - 14
Main Authors Chohan, Priyanka, Dashwood, Mark, Theodoulou, George, Reed, Hannah, Kuruvilla, Tarun
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Ltd 01.10.2022
Wiley Subscription Services, Inc
Subjects
Alzheimer's disease
Biomarkers
Online AccessGet full text

Cover

More Information
Summary:Blood‐based biomarkers for identifying Alzheimer's disease (AD) pathology have been of considerable interest over the past decade and can offer a significant advantage over the currently available and validated cerebrospinal fluid and positron emission tomography biomarkers in terms of cost, invasiveness and accessibility. This review explores the role of three blood‐based biomarkers; plasma amyloid β, tau and neurofilament light chain, and their combination, in the identification of AD pathology and how they may be utilised in clinical practice.
ISSN:1367-7543
1931-227X
DOI:10.1002/pnp.764